Thyroid hormones for euthyroid patients with simple goiter growing over time: a survey of European thyroid specialists
Background Treatment of simple goiter (SG) growing over time with thyroid hormone (TH) therapy is discouraged by international guidelines. Purpose To ascertain views of European thyroid specialists about TH treatment for euthyroid patients with growing SG and explore associations with management cho...
Gespeichert in:
Veröffentlicht in: | Endocrine 2025-01, Vol.87 (1), p.262-272 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Treatment of simple goiter (SG) growing over time with thyroid hormone (TH) therapy is discouraged by international guidelines.
Purpose
To ascertain views of European thyroid specialists about TH treatment for euthyroid patients with growing SG and explore associations with management choice.
Methods
Online survey on the use of TH for growing SG among thyroid experts from 28 European countries.
Results
The response rate was 31.5% (5430/17,247). Most respondents were endocrinologists. Twenty-eight percent asserted that TH therapy may be indicated in euthyroid patients with a growing SG. National and regional differences were noted, from 7% of positive responses in The Netherlands to 78% in Czech Republic (
p
60, respectively), and working in areas of former iodine insufficiency (OR 1.24, 95% CI 1.03–1.50). TH was less frequently prescribed by endocrinologists (OR 0.77, 95% CI 0.62-0.94) and respondents working in Southern Europe (OR 0.40, 95% CI 0.33–0.48), Northern Europe (OR 0.28, 95% CI 0.22–0.36) and Western Asia (OR 0.16, 95% CI 0.11–0.24) compared to Western Europe. Associations with respondents’ sex, country, availability of national thyroid guidelines, and gross national income per capita were absent or weak.
Conclusions
Almost a third of European thyroid specialists support treating SG with TH, contrary to current guidelines and recommendations. This calls for urgent attention. |
---|---|
ISSN: | 1559-0100 1559-0100 |
DOI: | 10.1007/s12020-024-04002-z |